AI-generated summary
The authors report a randomized, blinded split-face trial comparing 532 nm and 940 nm diode lasers for facial telangiectasias, assessed by photographs. They found both wavelengths improved telangiectasias, with 940 nm showing greater improvement and fewer side effects such as erythema, crusting and swelling. The authors describe the 940 nm wavelength as a novel one previously reported only in case reports.
- Who or what was studied
- Patients with facial telangiectasias; 24 facial anatomic sites were treated
- Wavelengths
- 532, 940 nm
- Limits stated in the abstract
- The abstract does not state the total number of patients, and the sample size is small enough that the authors' conclusions on superiority rest on a limited number of treated sites.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on onlinelibrary.wiley.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 532 nm, 940 nm
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Wavelength, Laser, Randomized controlled trial. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.